| Literature DB >> 33082791 |
Mohammad Moein Vakilzadeh1, Amirhossein Heidari1, Ali Mehri1, Matin Shirazinia1, Fereshte Sheybani2,3, Ehsan Aryan4, HamidReza Naderi2, Mona Najaf Najafi3, Marjan Varzandeh2.
Abstract
Background: Antimicrobial resistance among community-acquired uropathogens is an emerging concern over the past decades that warrants a continuing reevaluation of the appropriateness of recommended empiric antimicrobial regimens for treatment of urinary tract infections (UTIs). Aims: To describe the microbial spectrum and resistance profile of community-acquired uropathogens and predictors of isolation of resistant strains.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33082791 PMCID: PMC7556082 DOI: 10.1155/2020/3439497
Source DB: PubMed Journal: J Environ Public Health ISSN: 1687-9805
Characteristics of patients.
| Age (years) | 40 (30, 62) |
| Age groups | |
| Children (1 mon–<15 yrs) | 27 (8.2) |
| Young adults (≥15–<65 yrs) | 240 (72.9) |
| The elderly (≥65 yrs) | 62 (18.8) |
| Gender (female, %) | 276 (83.6) |
| Underlying comorbidities | |
| Cardiovascular disorders | 62 (21.8) |
| Diabetes mellitus | 57 (20.1) |
| CKD/ESRD | 7 (2.5) |
| Kidney transplant | 5 (1.8) |
| Others | 17 (5.9) |
| Patients with no underlying comorbidities | 156 (54.9) |
| Urinary catheter | 22 (7.5) |
| Pregnant | 20 (6.7) |
| Exposure to antibiotics within the past 3 months | 146 (49.7) |
| Hospital admission within the past 3 months | 32 (10.8) |
| Previous history of UTIs | 192 (65.1) |
| Isolated uropathogens | |
| | 201 (60.9) |
| | 46 (13.9) |
| | 27 (8.2) |
| CoNS | 20 (6.1) |
| | 10 (3) |
| | 6 (1.8) |
| | 5 (1.5) |
| | 4 (1.2) |
| Others | 11 (3.3) |
CKD: chronic kidney disease; ESRD: end-stage renal disease; CoNS: coagulase-negative staphylococci. Values are represented by the number of patients with specific characteristics (percent) for nominal variables and by median (25th quartile, 75th quartile) for quantitative variables. None of the patients was hospitalized at the time or a few days before they were included in the study.
Antimicrobial susceptibility profile of the most common isolated uropathogens.
|
|
|
| |
|---|---|---|---|
| Ampicillin | 2/34 (5.9) | 0/10 (0) | 12/13 (92.3) |
| Amoxicillin | 8/42 (11) | 0/12 (0) | 2/3 (66.7) |
| Nalidixic acid | 54/123 (43.9) | 16/25 (64) | NA |
| Ciprofloxacin | 71/120 (59.2) | 21/29 (72.4) | NA |
| Gentamicin | 113/156 (72.4) | 25/36 (69.4) | 3/5 (60) |
| Ceftriaxone | 67/109 (61.5) | 25/29 (86.2) | NA |
| Cefixime | 27/36 (75) | 9/11 (81.8) | NA |
| Cephalexin | 1/26 (3.8) | 4/9 (44.4) | NA |
| Tetracycline | 5/40 (12.5) | 5/13 (38.5) | 8/24 (33.3) |
| Nitrofurantoin | 108/121 (89.3) | 18/30 (60) | 12/12 (100) |
| TMP-SMX | 69/153 (45.1) | 21/34 (61.8) | NA |
NA: not applicable; TMP-SMX: trimethoprim-sulfamethoxazole.
Univariate analysis of the risk factor for community-acquired urinary tract infections caused by ciprofloxacin-resistant E. coli strains.
| Characteristics | Ciprofloxacin |
| OR (95% CI) |
| TMP-SMX |
| OR (95% CI) |
| |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistant | Sensitive | Resistant | Sensitive | ||||||||
| Age group (years) | 0–14 | 2 [ | 6 (75) | 0.081 | 1.084 (0.496–2.370) | 0.839 | 4 (33.3) | 8 (66.7) | 0.721 | 2.057 (1.066–3.972) | 0.032 |
| 15–64 | 40 (43) | 53 (57) | 46 (41.4) | 65 (58.6) | |||||||
| ≥65 | 7 (36.8) | 12 (63.2) | 19 (63.3) | 11 (36.7) | |||||||
|
| |||||||||||
| Gender (female) | 40 (40) | 59 (59.6) | 0.101 | 1.106 (0.427–2.869) | 0.835 | 61 (48) | 66 (52) | −0.732 | 0.481 (0.195–1.186) | 0.112 | |
|
| |||||||||||
| Diabetes mellitus | 14 (58.3) | 10 (41.7) | 0.432 | 1.540 (0.473–5.011) | 0.473 | 12 (46.2) | 14 (53.8) | −0.049 | 0.952 (0.350–2.589) | 0.924 | |
|
| |||||||||||
| History of previous episodes of UTIs | 35 (46.7) | 40 (53.3) | 0.714 | 2.042 (0.904–4.609) | 0.068 | 46 (54.1) | 56 (54.9) | ||||
|
| |||||||||||
| Exposure to antibiotics in the past 3 months | 30 (54.5) | 25 (45.5) | 1.063 | 2.894 (1.333–6.285) | 0.007 | 34 (44.2) | 43 (55.8) | 0.087 | 1.091 (0.566–2.102) | 0.796 | |
|
| |||||||||||
| History of hospital admission in the past 3 months | 9 (64.3) | 5 (35.7) | 1.077 | 2.937 (0.916–9.419) | 0.070 | 8 (50) | 8 (50) | 0.292 | 1.339 (0.474–3.787) | 0.582 | |
TMP-SMX: trimethoprim-sulfamethoxazole.